Загрузка...
AURIEL‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis
BACKGROUND: MSB11022 is a proposed adalimumab biosimilar. OBJECTIVES: To compare the efficacy, safety and immunogenicity of MSB11022 with reference adalimumab. METHODS: AURIEL‐PsO was a double‐blind randomized controlled equivalence trial, in which patients with moderate‐to‐severe chronic plaque‐typ...
Сохранить в:
| Опубликовано в: : | Br J Dermatol |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7027805/ https://ncbi.nlm.nih.gov/pubmed/31206593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.18220 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|